GlassScriptPhysician profile
Brandon C Danford
NPI 1669850426
$21,315.75
in general payments reported to CMS, 2019-2025
37 companies · $4,163 in 2025
The $4,163 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $927 · 2021: $2,317 · 2022: $4,377 · 2023: $5,166 · 2024: $3,924 · 2025: $4,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $700 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,387.47 |
| Consulting Fee | $700.00 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,601.26 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Epi Health, LLC | $1,552.20 | 2019-2022 | |
| Galderma Laboratories, L.P. | $1,543.67 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Genzyme Corporation | $1,537.36 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $1,218.40 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $1,157.23 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $1,091.91 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $893.43 | 2019-2025 | |
| Janssen Biotech, INC. | $821.56 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Leo Pharma INC. | $815.36 | 2020-2025 | Adbry, Anzupgo |
| Allergan, INC. | $760.96 | 2019-2022 | |
| Pfizer INC. | $689.91 | 2019-2025 | |
| Dermavant Sciences, INC. | $602.57 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $582.68 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Incyte Corporation | $581.57 | 2021-2025 | Opzelura |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $532.23 | 2020-2025 | Otezla, Otezla |
| Botanix Sb INC | $480.75 | 2025 | Sofdra |
| Almirall LLC | $421.54 | 2021-2025 | Seysara |
| Ucb, INC. | $420.23 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $407.37 | 2022-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $342.64 | 2020-2025 | Jublia, Cabtreo, Arazlo |
| Revance Therapeutics, INC. | $328.58 | 2024-2025 | Daxxify, Daxi |
| Mayne Pharma Commercial LLC | $270.75 | 2019-2025 | |
| Kyowa Kirin, INC. | $131.45 | 2023 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.14 | 2022-2024 | Spevigo |
| Organon LLC | $96.10 | 2025 | Vtama |
| Tactile Systems Technology INC | $66.11 | 2019-2020 | |
| Journey Medical Corporation | $47.61 | 2021-2022 | |
| Medimetriks Pharmaceuticals, INC. | $39.43 | 2021-2025 | Clindacin Etz, Neo-Synalar |
| Lnhc, INC | $28.18 | 2025 | Zelsuvmi |
| Dermira, INC. | $27.06 | 2021 | |
| Verrica Pharmaceuticals INC. | $21.65 | 2023 | Ycanth |
| Dusa Pharmaceuticals, INC. | $20.97 | 2019 | |
| Nabriva Therapeutics, Plc | $19.68 | 2022 | |
| Smith+Nephew, INC. | $14.94 | 2024 | Grafix Pl |
| Strata Skin Sciences, INC. | $14.55 | 2025 | Xtrac |
| Paratek Pharmaceuticals, INC. | $13.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Danford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.